Virksomheden fremlagde informationer, som blev anvendt i vurderingen af aliskiren, og fra den offentliggjorte dokumentation til støtte for dens ansøgning for Rasilez HCT samt informationer fra yderligere undersøgelser.
The company presented information used in the assessment of aliskiren and from the published literature to support its application for Rasilez HCT, as well as information from additional studies.